Cemiplimab approved for the treatment of non-small cell lung cancer

Cemiplimab is a new type of humanized anti-PD-1 monoclonal antibody that has made significant progress in the field of immuno-oncology treatment in recent years. For the treatment of non-small cell lung cancer (NSCLC), especially for the treatment of advanced patients, cimepilimab has been approved by regulatory agencies in many countries and has become one of the important immunotherapy drugs. In 2021, the United StatesFDA approved cimepilimab for the treatment ofPD-L1expression ≥50% It is especially suitable for patients with advanced non-small cell lung cancer without EGFR, ALK and ROS1 gene mutations. This approval was mainly based on data from the EMPOWER-Lung 1 clinical trial, which showed that cimepilimab monotherapy had significant advantages in extending patients' progression-free survival (PFS) and overall survival (OS) compared with traditional chemotherapy, and significantly improved the prognosis of patients.

On this basis, cimepilimab has further expanded its indications. In 2022, FDA approved cimepilimab combined with platinum-based chemotherapy for the treatment of patients with advanced non-small cell lung cancer without EGFR/ALK/ROS1 gene mutations, and no longer limited the PD-L1 expression level. The approval comes from the EMPOWER-Lung 3 clinical trial. The results of the trial showed that the overall survival and progression-free survival of patients in the combination group were significantly better than those in the chemotherapy alone group, demonstrating the broad applicability and powerful efficacy of the drug in the treatment of non-small cell lung cancer. This provides new options for effective treatment for more patients with different PD-L1 expression levels, especially those with low or unclear PD-L1 expression.

The approval of cimepilimab was based on data support from multiple key clinical trials. EMPOWER-Lung 1The trial included 712patients with PD-L1 high expression. The median overall survival of the cimepilimab group reached 26.1 months, which was significantly better than that of the chemotherapy group13.3 months, and the progression-free survival was also significantly prolonged. The EMPOWER-Lung 3 trial further confirmed the efficacy of the drug in combination with chemotherapy for all PD-L1 expressing patients, especially in terms of prolonging survival time and improving quality of life. Multiple data also show that the drug is safe and well-tolerated, with controllable side effects, making it an important member of the field of immunotherapy for advanced non-small cell lung cancer.

Reference materials:https://www.libtayohcp.com/